Clinical Trials • College News • Research Ohio State Launches Clinical Trial for Promising New Treatment for Acu...
New university findings highlight potential implications for dogs, cancer, and veterinary practice.
Supported in part by a National Institutes of Health One Health grant, the study also aims to advance translational research between human and veterinary medicine, given the lack of effective treatments for both.
Acute pancreatitis is a painful, life-threatening condition that affects an estimated 1.8 million dogs and accounts for more than 330,000 hospital admissions in humans each year in the United States.
A new clinical trial is now enrolling canine patients, offering hope for improving treatment.
Lamassu Pets, the veterinary division of Lamassu Biotech , and The Ohio State University College of Veterinary Medicine Blue Buffalo Veterinary Clinical Trials Office ( BBVCTO ) have begun testing a canine-specific application of RABI-767, a novel therapeutic targeting acute pancreatitis, a life-threatening condition that currently has no effective treatments in either human or veterinary medicine.
The drug is also being studied in human clinical trials.
The trial, which is supported by the National Institutes of Health (NIH), involves a single injection of the drug delivered directly around the pancreas.
The therapy aims to mitigate symptoms, reduce complications and protect against organ failure.
“For dog owners, this trial provides an opportunity to contribute to insights that could lead to breakthroughs benefiting both pets and people,” said Adam Rudinsky, DVM, associate professor in Ohio State’s Department of Veterinary Clinical Sciences.
“This clinical trial targeting acute pancreatitis in dogs is crucial for advancing veterinary care and improving human health through translational medicine.” The trial aims to provide insights into potential treatment and dosing strategies for dogs with acute pancreatitis.
Canine acute pancreatitis is often a painful, life-threatening diagnosis that can leave them hospitalized for days, or worse,” said Gabi Hanna, MD, CEO of Lamassu Biotech.
“The veterinarians at Ohio State are highly respected in their field, and this clinical trial has the potential to make a significant impact on the field of veterinary medicine.
The report adds to ongoing university-led research relevant to veterinary medicine, animal health, and clinical decision-making.
Source university website: Ohio State University College of Veterinary Medicine
Comments
Related Articles
Copyright © 2026 - All Rights Reserved
ISSN 2768-198X
List
Add
Please enter a comment